Novel automated AIMLAM for diagnosis of Mycobacterium tuberculosis
Future Microbiology · 2024
DOI: 10.2217/fmb-2024-0025 ↗Kurz gefasst
Fachartikel in der Zeitschrift Future Microbiology, 2024. Verfasst von Liang Ruixia und 4 weiteren Autor:innen. Beteiligte Einrichtung: Henan Provincial Chest Hospital, Henan Infectious Diseases (TB) Clinical Research Center. No. 1, Weiwu Road, Zhengzhou, Henan Province. Hauptthemen laut MEDLINE: Mycobacterium tuberculosis, Tuberculosis, Lipopolysaccharides, Sensitivity and Specificity. Die Arbeit nennt 53 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Aim
A rapid and precise diagnostic method is crucial for timely intervention and management of tuberculosis. The present study compared the diagnostic accuracy of a novel lipoarabinomannan (LAM) antigen test, AIMLAM, for tuberculosis in urine samples. Methodology: The study subjected 106 TB suspects to smear microscopy, MGIT, GeneXpert and AIMLAM.
Results
Among 106, smear microscopy identified 36 as positive (33%) (sensitivity; 70.93%, 95% CI (60.14-80.22%), while MGIT showed 38 positive (36.8%). GeneXpert detected 59 positives (sensitivity; 96.83, 95% CI (89.00-99.61%)). AIMLAM declared 61 as positive (57.5%) (sensitivity; 100.00, 95% CI (94.13-100.00%) and 45 as negative (42.5%).
Conclusion
Overall, AIMLAM demonstrated better diagnostic accuracy than GeneXpert Assay, smear microscopy and MGIT liquid culture in urine samples. This study describes a new way to detect tuberculosis, called AIMLAM. Unlike traditional methods that use sputum or blood, AIMLAM tests urine samples and bodily fluids. It is automated and uses easily accessible samples to identify a tuberculosis infection, so may be a convenient and noninvasive option for healthcare providers. The test shows promising results in terms of accuracy and sensitivity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Henan Provincial Chest Hospital, Henan Infectious Diseases (TB) Clinical Research Center. No. 1, Weiwu Road, Zhengzhou, Henan Province.
ORCID-Profile: Li Jiankang
Zitieren
APA
Ruixia, L., Jiankang, L., Hongmei, S., Han, W., & Chang, Z. (2024). Novel automated AIMLAM for diagnosis of Mycobacterium tuberculosis. Future Microbiology. https://doi.org/10.2217/fmb-2024-0025
Vancouver
Ruixia L, Jiankang L, Hongmei S, Han W, Chang Z. Novel automated AIMLAM for diagnosis of Mycobacterium tuberculosis. Future Microbiology. 2024. doi:10.2217/fmb-2024-0025
BibTeX
@article{Ruixia2024,
author = {Ruixia, Liang and Jiankang, Li and Hongmei, Shi and Han, Wu and Chang, Zhao},
title = {Novel automated AIMLAM for diagnosis of Mycobacterium tuberculosis},
journal = {Future Microbiology},
year = {2024},
doi = {10.2217/fmb-2024-0025}
}
EUVIMED